Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03075215 · ClinicalTrials.gov registry record

Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry

A clinical trial, sponsored by Boston Scientific Corporation.

Completed
Registry status
2,044
Enrollment target

NCT03075215 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,044 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03075215 has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
2,044 participants
Enrollment target

Study Summary

To learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better response than others. A subset of SMART Registry subjects will contribute to the NG4 Post Market Clinical Follow Up (PMCF) Cohort whose objective is collecting data on the NG4 CRT-D features and device usage in a real world setting and monitor long term safety associated with these devices to support CE Mark.

Interventions

  • DEVICE Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Trial Details

FieldValue
Enrollment Target 2,044 participants
Start Date 2017-04-14
Est. Completion 2021-11-15

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT03075215

The ClinicalTrials.gov registry entry for NCT03075215 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,044 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) is the first listed.

NCT03075215 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03075215 about?

NCT03075215 is a clinical study titled "Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry". To learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better ...

What is the current status of trial NCT03075215?

This trial is currently completed. The enrollment target is 2,044 participants. The study started on 2017-04-14. Estimated completion is 2021-11-15.

What interventions are being tested in trial NCT03075215?

The interventions under investigation include: Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) (DEVICE).

Who is sponsoring clinical trial NCT03075215?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.